2020 American Transplant Congress
Donor-Derived Cell-Free DNA (dd-cfDNA) Levels in Stable Pediatric Kidney Transplant Recipients
Pediatrics, Eastern Virginia Medical School, Norfolk, VA
*Purpose: Among adult kidney transplant recipients, donor-derived cell-free DNA (dd-cfDNA) has been validated as a highly sensitive biomarker for graft rejection. Unfortunately, few data are…2020 American Transplant Congress
Late De Novo Donor Specific Antibodies in Steroid Free Immunosuppression and Delayed Graft Function
Temple University School of Medicine, Philadelphia, PA
*Purpose: Donor Specific Antibodies (DSA) have been implicated in acute and chronic antibody-mediated rejection. Once developed, they tend to be persistent and lead to transplant…2020 American Transplant Congress
Value of dd-cfDNA When Considering Recipient Ethnicity to Further to Help Risk Stratify Transplant Recipients
*Purpose: Within the modern era of kidney transplantation, African American (AA) transplant recipients continue to experience disproportionately higher rates of allograft loss. A combination of…2020 American Transplant Congress
Post-Transplant Rebound and Not Baseline Anti-A Titers are Associated with Acute Antibody-Mediated Rejection in A2– to B/O Incompatible Kidney Transplantation
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Decreased antigen expression among blood group A subtype 2 (A2) donor kidneys allows these organs to be considered as universal donors; under the new…2020 American Transplant Congress
Is Azathioprine the Right Choice in De Novo Lung Transplantation?
*Purpose: The antiproliferative of choice in lung transplantation (LT) remains controversial. Limited data exists on azathioprine (AZA) dose reductions or the conversion of AZA to…2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…2020 American Transplant Congress
Exosomes Containing Kidney Self-Antigens (Collagen Iv, Fibronectin, Perlecan) Predicts Progression of Chronic Immune Injury in Kidney Transplant Recipients
*Purpose: We have shown that circulating exosome with lung self-antigens (SAgs) are detectable 1 year prior to chronic lung allograft dysfunction, independent of circulating antibodies.…2020 American Transplant Congress
Activated CD27+CD21– Subset Dominate the Memory B Cell Response During Antibody-Mediated Rejection of Kidney Allografts
1Surgery, University of Pittsburgh, Pittsburgh, PA, 2Inserm UMR 976, Paris, France
*Purpose: The role of alloreactive memory B (mB) cells in the pathogenesis of antibody-mediated rejection (ABMR) is increasingly recognized. Yet, a comprehensive characterization of mB…2020 American Transplant Congress
Extracellular Vesicles Mediate Endothelial to Mesenchymal Transition and Tubular Senescence in Renal Antibody- Mediated Rejection by Inducing Complement Activation
Emergency and Organ Transplantation, University of Bari, Bari, Italy
*Purpose: EVs (Extracellular vesicles), circulating microparticles able to mediate cell-to cell communication, are emerging as pivotal in different kidney diseases. Renal Antibody-Mediated Rejection (AMR) is…
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- …
- 172
- Next Page »